478 related articles for article (PubMed ID: 28685687)
1. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.
Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V
Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687
[TBL] [Abstract][Full Text] [Related]
2. Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer's disease lead to depression?
Mitić M; Lazarević-Pašti T
Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):841-856. PubMed ID: 33999717
[No Abstract] [Full Text] [Related]
3. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection.
Singh M; Kaur M; Kukreja H; Chugh R; Silakari O; Singh D
Eur J Med Chem; 2013; 70():165-88. PubMed ID: 24148993
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
McHardy SF; Wang HL; McCowen SV; Valdez MC
Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
[TBL] [Abstract][Full Text] [Related]
5. Acetylcholinesterase inhibitors: a patent review (2008 - present).
Pohanka M
Expert Opin Ther Pat; 2012 Aug; 22(8):871-86. PubMed ID: 22768972
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling, docking and ADMET studies applied to the design of a novel hybrid for treatment of Alzheimer's disease.
da Silva CH; Campo VL; Carvalho I; Taft CA
J Mol Graph Model; 2006 Oct; 25(2):169-75. PubMed ID: 16413803
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Acetylcholinesterase (AChE): A Potential Therapeutic Target to Treat Alzheimer's Disease.
Li Y; Zhang XX; Jiang LJ; Yuan L; Cao TT; Li X; Dong L; Li Y; Yin SF
Chem Biol Drug Des; 2015 Oct; 86(4):776-82. PubMed ID: 25736722
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer's disease.
de Almeida JR; Figueiro M; Almeida WP; de Paula da Silva CHT
Future Med Chem; 2018 May; 10(9):1037-1053. PubMed ID: 29676170
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.
Galdeano C; Viayna E; Arroyo P; Bidon-Chanal A; Blas JR; Muñoz-Torrero D; Luque FJ
Curr Pharm Des; 2010; 16(25):2818-36. PubMed ID: 20698824
[TBL] [Abstract][Full Text] [Related]
10. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease.
Akıncıoğlu H; Gülçin İ
Mini Rev Med Chem; 2020; 20(8):703-715. PubMed ID: 31902355
[TBL] [Abstract][Full Text] [Related]
11. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B; Singh N
Bioorg Med Chem; 2012 Feb; 20(3):1175-80. PubMed ID: 22257528
[TBL] [Abstract][Full Text] [Related]
12. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease.
Rees TM; Brimijoin S
Drugs Today (Barc); 2003 Jan; 39(1):75-83. PubMed ID: 12669110
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine.
Jiang X; Liu C; Zou M; Xie H; Lin T; Lyu W; Xu J; Li Y; Feng F; Sun H; Liu W
Eur J Med Chem; 2021 Nov; 223():113663. PubMed ID: 34198150
[TBL] [Abstract][Full Text] [Related]
14. [Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].
Yang WC; Sun Q; Yu NX; Zhu XL; Yang GF
Yao Xue Xue Bao; 2012 Mar; 47(3):313-21. PubMed ID: 22645754
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors.
Basiri A; Xiao M; McCarthy A; Dutta D; Byrareddy SN; Conda-Sheridan M
Bioorg Med Chem Lett; 2017 Jan; 27(2):228-231. PubMed ID: 27914796
[TBL] [Abstract][Full Text] [Related]
16. Acetylcholinesterase and its inhibition in Alzheimer disease.
Lane RM; Kivipelto M; Greig NH
Clin Neuropharmacol; 2004; 27(3):141-9. PubMed ID: 15190239
[TBL] [Abstract][Full Text] [Related]
17. Natural products as sources of new lead compounds for the treatment of Alzheimer's disease.
Huang L; Su T; Li X
Curr Top Med Chem; 2013; 13(15):1864-78. PubMed ID: 23931437
[TBL] [Abstract][Full Text] [Related]
18. Withanolides: Biologically Active Constituents in the Treatment of Alzheimer's Disease.
Khan SA; Khan SB; Shah Z; Asiri AM
Med Chem; 2016; 12(3):238-56. PubMed ID: 26527154
[TBL] [Abstract][Full Text] [Related]
19. Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease.
Sivaraman B; Raji V; Velmurugan BA; Natarajan R
CNS Neurol Disord Drug Targets; 2022; 21(5):427-449. PubMed ID: 34602041
[TBL] [Abstract][Full Text] [Related]
20. Target Enzyme in Alzheimer's Disease: Acetylcholinesterase Inhibitors.
Saxena M; Dubey R
Curr Top Med Chem; 2019; 19(4):264-275. PubMed ID: 30706815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
